The United Nations Office on Drugs and Crime (UNODC). World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9). www.unodc.org/wdr2018/ (accessed 2 Jun 2020).Google Scholar

The United Nations Office on Drugs and Crime (UNODC). World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_1_EXECUTIVE_SUMMARY.pdf (accessed 2 April 2020).Google Scholar

National Institute of Drug Abuse (NIDA). Club Drugs. www.drugabuse.gov/drugs-abuse/club-drugs (accessed 2 April 2020).Google Scholar

The United Nations Office on Drugs and Crime (UNODC). Early Warning Advisory on New Psychoactive Substances.www.unodc.org/LSS/Page/NPS (accessed 2 April 2020).Google Scholar

Owie, RE, Gosney, P, Roney, A, O’Brien, A. Psychiatrists’ knowledge of novel psychoactive substances. Drugs and Alcohol Today 2017;17(3):178–85, https://doi.org/10.1108/DAT-03-2017-0011Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Luxembourg: Publications Office of the European Union, 2019.Google Scholar

Corazza, O, Schifano, F, Farre, M, et al. Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol. 2011 May;6(2):125–9.Google Scholar

Measham, F, Moore, K, Newcombe, R, Welch, Z. Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. Drugs Alcohol Today 2010;10(1):14–21.CrossRefGoogle Scholar

Measham, F, Wood, DM, Dargan, PI, Moore, K. The rise in legal highs: prevalence and patterns in the use of illegal drugs and first- and second-generation ‘legal highs’ in South London gay dance clubs. J Substance Use August 2011;16(4):263–72.Google Scholar

Brunt, TM, Poortman, A, Niesink, RJ, van den Brink, W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol. 2011 Nov;25(11):1543–7. doi:10.1177/0269881110378370Google Scholar

Home Office. Drug Misuse Declared: Findings from the 2011/12 Crime Survey for England and Wales (2nd Edition) July 2012. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/147938/drugs-misuse-dec-1112-pdf.pdf (accessed 1 April 2020)Google Scholar

Public Health England. Adult Substance Misuse Statistics from the National Drug Treatment Monitoring System (NDTMS) 1 April 2017 to 31 March 2018. November 2018 PHE publications gateway number: 2018575 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/752993/AdultSubstanceMisuseStatisticsfromNDTMS2017-18.pdf (accessed 1 April 2020)Google Scholar

Office of National Statistics. Deaths Related to Drug Poisoning in England and Wales. 2018 Registrations August 2019 www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2018registrations (accessed 2 April 2020)Google Scholar

Home Office. Seizures of Drugs in England and Wales, Financial Year Ending 2018 Statistical Bulletin 26/18 November 2018 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/754677/seizures-drugs-mar2018-hosb2618.pdf (accessed 2 April 2020).Google Scholar

European Monitoring Centre for Drugs and Drug Addiction and Europol. EU Drug Markets Report: In-Depth Analysis, EMCDDA–Europol Joint publications, 2016. Luxembourg: Publications Office of the European Union.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction and Europol. Drugs and the Darknet: Perspectives for Enforcement, Research and Policy, EMCDDA–Europol Joint publications, 2017. Luxembourg: Publications Office of the European Union.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction EMCDDA. Recent changes in Europe’s cocaine market. Results from an EMCDDA trendspotter study, 2018. Portugal, Lisbon: European Monitoring Centre for Drugs and Drug Addiction.Google Scholar

Clinical Guidelines on Drug Misuse and Dependence Update. Independent Expert Working Group (2017) Drug misuse and dependence: UK Guidelines on Clinical Management. London: Department of Health, 2017.Google Scholar

World Health Organisation International Classification of Diseases, 11th Revision (ICD-11) Disorders due to Substance Use or Addictive Behaviours https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1602669465 (accessed 2 April 2020).Google Scholar

National Institute for Health and Clinical Excellence. Drug Misuse: Psychosocial Interventions (Clinical Guideline 51). 2007.Google Scholar

National Institute for Health and Clinical Excellence. Drug Misuse in Over 16s: Opioid Detoxification Clinical Guideline. Published 25 July 2007.Google Scholar

National Institute for Health and Clinical Excellence. Alcohol Use Disorders: Harmful Drinking and Alcohol Dependence (Clinical Guidance 115: Evidence Update). 2013.Google Scholar

National Institute for Health and Clinical Excellence. Behaviour Change: Individual Approaches (PH 49). 2014.Google Scholar

Darke, S, Kaye, S, McKetin, R, et al. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008;27:253–62.Google Scholar

Pérez-Mañá, C, Castells, X, Torrens, M, Capellà, D, Farre, M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence (Review). Cochrane Database Syst Rev. 2013 Sep. 2;9:CD009695. doi:10.1002/14651858.CD009695.pub2Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The Levels of Use of Opioids, Amphetamines and Cocaine and Associated Levels of Harm: Summary of Scientific Evidence. March 2014.Google Scholar

Carvalho, M, Carmo, H, Costa, VM, et al. Toxicity of amphetamines: an update. Arch Toxicol. 2012 Aug;86(8):1167–231. doi:10.1007/s00204-012-0815–5Google Scholar

Henry, JA, Jeffreys, KJ, Dawling, S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (‘ecstasy’). Lancet. 1992;340:384–7.Google Scholar

Green, AR, O’Shea, E, Colado, MI. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol. 2004;500(1–3):3–13.Google Scholar

Boyer, EW, Shannon, M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20.Google Scholar

Dunkley, EJ, Isbister, GK, Sibbritt, D, Dawson, AH, Whyte, IM. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–42.Google Scholar

Sun-Edelstein, C, Tepper, SJ, Shapiro, RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008 Sep;7(5):587–96. doi:10.1517/14740338.7.5.587Google Scholar

Gillman, PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache 2010;50:264–72.Google Scholar

Huether, G, Zhou, D, Ruther, E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its congeners. J Neural Transm. 1997;104:771–94.Google Scholar

Parrott, AC. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav. 2002;71:837–44.Google Scholar

Turkel, SB, Nadala, JG, Wincor, MZ. Possible serotonin syndrome in association with 5-HT(3) antagonist agents. Psychosomatics. 2001;42:258–60.Google Scholar

Isbister, GK, Bowe, SJ, Dawson, A, Whyte, IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277–85.Google Scholar

Home Office. Drugs Misuse: Findings from the 2018/19 Crime Survey for England and Wales Statistical Bulletin: 21/19. 19 September 2019.Google Scholar

Bachia, K, Manib, V, Jeyachandranc, D, et al. Vascular disease in cocaine addiction. Atherosclerosis. 2017;262:154–62. doi:10.1016/j.atherosclerosis.2017.03.019.Google Scholar

Riezzo, I, Fiore, C, De Carlo, D, et al. Side effects of cocaine abuse: multiorgan toxicity and pathological consequences. Curr Med Chem. 2012;19(33):5624–46.Google Scholar

Henning, RJ, Wilson, LD, Glauser, JM. Cocaine plus ethanol is more cardiotoxic than cocaine or ethanol alone. Crit Care Med. 1994;22:1896–1906.CrossRefGoogle ScholarPubMed

Wiener, SE, Sutijono, D, Moon, CH, et al. Patients with detectable cocaethylene are more likely to require intensive care unit admission after trauma. Am J Emerg Med. 2010;28:1051.Google Scholar

Srisurapanont, M, Ali, R, Marsden, J, et al. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003;6(4):347–52.Google Scholar

Arunogiril, S, Foulds, JA, McKetin, R, Lubman, DI. A systematic review of risk factors for methamphetamine-associated psychosis. Aust N Z J Psychiatry 2018;52(6):514–29. DOI:10.1177/0004867417748750Google Scholar

Arunogiri, S, McKetin, R, Verdejo-Garcia, A, et al. The methamphetamine-associated psychosis spectrum: a clinically focused review. Int J Ment Health Addiction 2020;18:54–65. https://doi.org/10.1007/s11469-018–9934-4Google Scholar

McKentin, R. Methamphetamine psychosis: insights from the past. Addiction 2018;113(8):1522–27.Google Scholar

Rawson, RA, Ling, W. Clinical management: methamphetamine. In: Galanter, M, Kleber, HD, eds. Textbook of Substance Abuse Treatment, 2008 4th ed. pp. 169–79. Washington, DC, American Psychiatric Publishing.Google Scholar

Akiyama, K. Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence. Ann N Y Acad Sci.2006;1074:125–34.Google Scholar

Ma, J, Li, XD, Wang, TY, et al. Relationship between the duration of methamphetamine use and psychotic symptoms: A two-year prospective cohort study. Drug Alcohol Depend. 2018;187:363–69. doi:10.1016/j.drugalcdep.2018.03.023.Google Scholar

Glasner-Edwards, S, Mooney, LJ, Marinelli-Casey, P, et al. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev. 2010;29:12–20.Google Scholar

McKetin, R, Dawe, S, Burns, R, et al. The profile of psychiatric symptoms exacerbated by methamphetamine use. Drug and Alcohol Dependence 2016;61(1):104–9. http://dx.doi.org/10.1016/j.drugalcdep.2016.01.018Google Scholar

Bell, DS, Trethowan, WH. Amphetamine addiction and disturbed sexuality. Arch Gen Psychiatry. 1961;4:74–8.Google Scholar

Buchacz, K, McFarland, W, Kellogg, T, et al. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS. 2005;19:1423–4.Google Scholar

McKetin, R, Lubman, DI, Baker, A, et al. The relationship between methamphetamine use and heterosexual behaviour: evidence from a prospective longitudinal study. Addiction. 2018;113(7):1276–85. doi:10.1111/add.14181.Google Scholar

Bourne, A, Reid, D, Hickson, F, et al. A perfect storm? Modern technological and structural facilitators of drug use during sex among gay men in London. Poster presentation, 2014. Available from www.sigmaresearch.org.uk/files/Adam_Bourne_IAS_Melbourne_2014e_poster.pdf.Google Scholar

Gilbart, VL, Simms, I, Jenkins, C, et al. Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with Shigella flexneri in England and Wales. Sex Transm Infect. 2015;91(8):598–602. doi:10.1136/sextrans-2015-052014.Google Scholar

Hopwood, MN, Cama, E, Treloar, C. Methamphetamine use among men who have sex with men in Australia: A literature review. 2016. UNSW Australia: Centre for Social Research in Health.Google Scholar

Nichols, DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs. 1986;18:305–13.Google Scholar

De la Torre, RM. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Therapeutic Drug Monitoring. 2004;26(2):137–44.Google Scholar

Feduccia, AA, Holland, J, Mithoefer, MC. Progress and promise for the MDMA drug development program. Psychopharmacology 2018;235(2):561–71. doi 10.1007/s00213-017–4779-2.Google Scholar

Schenk, S, Newcombe, D. Methylenedioxymethamphetamine (MDMA) in psychiatry: pros, cons, and suggestions. J Clin Psychopharmacol 2018;38(6): 632–38. doi:10.1097/JCP.0000000000000962Google Scholar

Home Office. Drug Misuse: Findings from the 2017/18 Crime Survey for England and Wales. Statistical Bulletin, 14/18 July 2018.Google Scholar

Brunt, TM, Poortman, A, Niesink, RJ, van den Brink, W. Instability of the ecstasy market and a new kid on the block: Mephedrone. J Psychopharmacol, 2011;25:1543–47.Google Scholar

McElrath, K, Van Hout, MC. A preference for mephedrone: drug markets, drugs of choice, and the emerging ‘legal high’ scene. J Drug Issues. 2011;41(4):487–507.Google Scholar

EMCDDA. European drug report. Trends and developments 2015. Luxembourg: Publications Office of the European Union. 2015. Retrieved from https://www.emcdda.europa.eu/system/files/publications/2473/TD0116348ENN.pdfGoogle Scholar

Edland-Gryta, M, Sandberga, S, Pedersen, W. From ecstasy to MDMA: Recreational drug use, symbolic boundaries, and drug trends International Journal of Drug Policy 50;2017:1–8.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. Recent changes in Europe’s MDMA/ecstasy market, EMCDDA Rapid Communication. 2016. Luxembourg: Publications Office of the European Union.Google Scholar

Public Health Wales. PHILTRE Annual Report 2017–18: www.wales.nhs.uk/sitesplus/documents/888/Philtre%20Annual%20Report%202018%20FINAL.pdf (accessed 15 January 2019).Google Scholar

Ling, LH, Marchant, C, Buckley, NA, Prior, M, Irvine, RJ. Poisoning with the recreational drug paramethoxyamphetamine (‘death’). Med J Australia. 2001;174:453–5.Google Scholar

Baylen, CA. A review of the acute subjective effects of MDMA/ecstasy. Addiction. 2006;101(7):933–47.Google Scholar

Green, AR, Mechan, AO, Elliott, JM, O’Shea, E, Colado, MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacological Reviews. 2003;55(3):463–508.Google Scholar

Sáez-Briones, P, Hernández, A. MDMA (3, 4-methylenedioxymethamphetamine) analogues as tools to characterize MDMA-like effects: an approach to understand entactogen pharmacology. Current Neuropharmacology. 2013;11(5):521.Google Scholar

Degenhardt, L, Hall, W. The Health and Psychological Effects of ‘Ecstasy’ (MDMA) Use. National Drug and Alcohol Research Centre. University of New South Wales, 2010.Google Scholar

Rosenson, J, Smollin, C, Sporer, KA, Blanc, P, Olson, KR. Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med. 2007;49(2):164–71, 171.e1.Google Scholar

Rogers, G, Elston, J, Garside, R, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess. 2009;13(6):iii–iv, ix–xii. doi:10.3310/hta13050Google Scholar

Jahns, F-P, Auzinger, G, Pineau Mitchell, A. Too hot to handle: A case report of extreme pyrexia after MDMA ingestion. Therapeutic Hypothermia and Temperature Management 2018;8(3):173–75. doi:10.1089/ther.2018.0002Google Scholar

Grunau, BE, Wiens, MO, Brubacher, JR. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM. 2010;12(5):435–42.Google Scholar

Chang, JCYC. Late diagnosis of MDMA-related severe hyponatremia. Case Rep Intern Med. 2014;1(2):153.Google Scholar

Meehan, TJ, Bryant, SM, Aks, SE. Drugs of abuse: the highs and lows of altered mental states in the emergency department. Emerg Med Clin North Am. 2010;28(3):663–82. doi:10.1016/j.emc.2010.03.012.Google Scholar

Reddy, P, Mooradian, AD. Diagnosis and management of hyponatraemia in hospitalised patients. Int J Clin Pract, 2009;63(10):1494–508. doi:10.1111/j.1742-1241.2009.02103.Google Scholar

Parrott, AC. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol. 2005;19:71–83.Google Scholar

Raznahan, M, Hassanzadeh, E, Houshmand, A, et al. Change in frequency of acute and subacute effects of ecstasy in a group of novice users after 6 months of regular use. Psychiatr Danub. 2013;25(2):175–8.Google Scholar

Rogers, G, Elston, J, Garside, R, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess. 2009;13(6):iii–iv, ix–xii. doi:10.3310/hta13050.Google Scholar

Hermle, L, Spitzer, M, Borchardt, D, Kovar, KA, Gouzoulis, E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents?Neuropsychopharmacology. 1993;8(2):171–6.Google Scholar

Degenhardt, L, Bruno, R, Topp, L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010;107:1–10.Google Scholar

Bruno, R, Matthews, AJ, Topp, L, Degenhardt, L, Gomez, R, Dunn, M. Can the severity of dependence scale be usefully applied to ‘ecstasy’? Neuropsychobiology. 2009;60(3–4):137–47. doi:10.1159/000253550Google Scholar

Baumann, MH, Partilla, JS, Lehner, KR. Psychoactive ‘bath salts’: Not so soothing. European Journal of Pharmacology 2013;698:1–5. doi:10.1016/j.ejphar.2012.11.020Google Scholar

Majchrzak, M, Celiński, R, Kuś, P, et al. The newest cathinone derivatives as designer drugs: an analytical and toxicological review. Forensic Toxicol 2018;36:33–50 https://doi.org/10.1007/s11419-017–0385-6Google Scholar

Glennon, RA, Dukat, M. Synthetic cathinones: a brief overview of overviews with applications to the forensic sciences. Ann Forensic Res Anal. 2017;4(2):1040.Google Scholar

Daveluy, A, Géniaux, H, Eiden, C, et al. Illicit drugs or medicines taken by parachuting. Fundamental & Clinical Pharmacology 2016;30(2):185–190.Google Scholar

Ross, EA, Reisfield, GM, Watson, MC, Chronister, CW, Goldberger, BA. Psychoactive ‘bath salts’ intoxication with methylenedioxypyrovalerone. The American Journal of Medicine 2012;125(9):854–8. doi: 10.1016/j.amjmed.2012.02.019 PMID:22682791Google Scholar

Karila, L, Billieux, J, Benyamina, A, Lançon, C, Cottencin, O, The effects and risks associated to mephedrone and methylone in humans: a review of the preliminary evidences. Brain Research Bulletin. 2016;126:61–7.Google Scholar

Gatch, MB, Forster, MJ. Entactogenic effects of synthetic cathinones. Abstracts/Drug and Alcohol Dependence 2017;171:e2–e226.Google Scholar

Colon-Perez, LM, Tran, K, Thompson, K, et al. The psychoactive designer drug and bath salt constituent MDPV causes widespread disruption of brain functional connectivity. Neuropsychopharmacology 2016;41:2352–65.Google Scholar

Homman, L, Seglert, J, Morgan, MJ. An observational study on the sub-acute effects of mephedrone on mood, cognition, sleep and physical problems in regular mephedrone users. Psychopharmacology 2018;235(9):2609–18. doi:10.1007/s00213-018–4953-1Google Scholar

Wood, DM, Davies, S, Greene, SL, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol. 2010;48:924–7.Google Scholar

Wood, DM, Davies, S, Puchnarewicz, M, et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol. 2010;6(3):327–30.Google Scholar

Fleckenstein, AE, Volz, TJ, Riddle, EL, Gibb, JW, Hanson, GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681–98.Google Scholar

Dargan, PI, Sedefov, R, Gallegos, A, Wood, DM. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal. 2011;3(7–8):454–63. doi:10.1002/dta.312Google Scholar

German, CL, Fleckenstein, AE, Hanson, GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 2014;97:2–8.Google Scholar

Prosser, JM, Nelson, LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012;8:33–42.Google Scholar

Woo, TM, Hanley, J. ‘How do they look?’ Identification and treatment of common ingestions in adolescents. J Pediatr Health Care. 2013;27(2):135–44. doi:10.1016/j.pedhc.2012.12.002.Google Scholar

Simmler, LD, Buser, TA, Donzelli, M, et al. Pharmacological characterization of designer cathinones in vitro. British Journal of Pharmacology 2013;168:458–470.Google Scholar

EMCDDA. Technical Report on 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (3,4-methylenedioxypyrovalerone, MDPV) Annex 2. Prepared by Ms Alison M Dines, Dr David M Wood and Dr Paul I Dargan: www.emcdda.europa.eu/attachements.cfm/att_228256_EN_TDAK14003ENN.pdfGoogle Scholar

Advisory Council on the Misuse of Drugs (ACMD). Consideration of the Cathinones. Home Office, 2010.Google Scholar

Winstock, A, Mitcheson, L, Ramsey, J, et al. Mephedrone: use, subjective effects and health risks. Addiction. 2011;106(11):1991–6.Google Scholar

EMCDDA. Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances 2011. www.emcdda.europa.eu/system/files/publications/571/TDAK11001ENC_WEB-OPTIMISED_FILE_280269.pdfGoogle Scholar

EMCDDA. Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone). In accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances.2010. www.emcdda.europa.eu/attachements.cfm/att_116485_EN_Risk%20Assessment%20Report%20on%20mephedrone.pdfGoogle Scholar

Hope, VD, Cullen, KJ, Smith, J, et al. 2016. Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection? Eurosurveillance, 21(19). doi:10.2807/1560-7917.ES.2016.21.19.30225Google Scholar

Maitre, M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol. 1997;51:337–61.Google Scholar

Schep, LJ, Knudsen, K, Slaughter, RJ, Vale, JA, Mégarbane, B. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila). 2012;50(6):458–70. doi:10.3109/15563650.2012.7022Google Scholar

Yanagihara, Y, Kariya, S, Ohtani, M, et al. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2001;29:887–90.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the Risk Assessment of GHB in the Framework of the Joint Action on New Synthetic Drugs. 2002. www.emcdda.europa.eu/system/files/publications/175/Risk4_62945.pdfGoogle Scholar

Carter, LP, Chen, W, Wu, H, et al. Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV). Drug and Alcohol Dependence 2005;78(1):91–9 https://doi.org/10.1016/j.drugalcdep.2004.10.002Google Scholar

Miróa, Ò, Galiciaa, M, Darganb, P, et al. Euro-DEN Research Group: Intoxication by gamma hydroxybutyrate and related analogues: Clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicology Letters 2017;277:84–91 https://doi.org/10.1016/j.toxlet.2017.05.030Google Scholar

Degenhardt, L, Darke, S, Dillon, P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend. 2002;67(1):89–94.Google Scholar

Chin, RL, Sporer, KA, Cullison, B, Dyer, JE, Wu, TD. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med. 1998;31(6):716–22.Google Scholar

TOXBASE. www.toxbase.org/Chemical-incidents/Management-Pages/GHB-overdose–features-and-management1/ (accessed 16 January 2019).Google Scholar

Reeves, J, Duda, R. GHB/GBl intoxication and withdrawal: a review and case presentation. Addict Disord Treatment. 2003;2:25–8.Google Scholar

McDonough, M, Kennedy, N, Glasper, A, Bearn, J. Clinical features and management of gammahydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend. 2004;75:3–9.Google Scholar

van Noorden, MS, Mol, T, Wisselink, J, Kuijpers, W, Dijkstra, BA. Treatment consumption and treatment re-enrollment in GHB-dependent patients in The Netherlands. Drug and Alcohol Dependence. 2017;176:96–101.Google Scholar

Bell, J, Collins, R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction. 2011;106(2):442–7. doi:10.1111/j.1360-0443.2010.03145.x.Google Scholar

Lingford-Hughes, A, Patel, Y, Bowden-Jones, O, et al. Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial. Trials 2016;17:472. https://doi.org/10.1186/s13063-016–1593-9Google Scholar

Harmen, B, Kamal, RM, de Jong, CAJ, Dijkstra, BAG, Arnt, FAS. Baclofen to prevent pelapse in Gamma-Hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, nonrandomized, controlled trial. CNS Drugs 2018;32:437–42 https://doi.org/10.1007/s40263-018–0516-6Google Scholar

Dijkstra, BAG, Kamal, RM, van Noordena, MS, et al. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: The Dutch GHB monitor project. Drug and Alcohol Dependence 2017:170164–173 http://dx.doi.org/10.1016/j.drugalcdep.2016.11.014Google Scholar

Pereira, FR, McMaster, M, van den Brink, W, van Wingen, G. Effects of gamma hydroxybutyrate (GHB) induced coma on long-term memory and brain function. Amsterdam Neuroscience: www.ecnp.eu/presentationpdfs/71/P.6.d.006.pdf (accessed 6 April 2020).Google Scholar

UNODC. Fentanyl and its analogues – 50 years on. Global SMART Update. 2017;17: www.unodc.org/documents/scientific/Global_SMART_Update_17_web.pdf (accessed 23 March 2020).Google Scholar

UNODC. Understanding the global opioid crisis. Global SMART Update. 2019;21: www.unodc.org/documents/scientific/Global_SMART_21_web_new.pdf (accessed 27 March 2020).Google Scholar

Ayres, WA, Starsiak, MJ, Sokolay, P. The bogus drug: three methyl and alpha methyl fentanyl sold as ‘China White’. J Psychoactive Drugs 1981;13(1):91–3.Google Scholar

Pearson, J, Poklis, J, Poklis, A, et al. Postmortem toxicology findings of acetyl fentanyl, fentanyl, and morphine in heroin fatalities in Tampa, Florida. Acad Forensic Pathol. 2015;5(4):676–89.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2017: Trends and Developments. 2017. Luxembourg: Publications Office of the European Union.Google Scholar

Frank, RG, Pollack, HA. Addressing the fentanyl threat to public health. N Engl J Med 2017;376(7):605–7. doi:10.1056/NEJMp1615145Google Scholar

Suzuki, J, El-Haddad, S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2016;171:107–16. doi:10.1016/j.drugalcdep. 2016.11.033Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. Report on the Risk Assessment of Nphenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (Furanylfentanyl) in the Framework of the Council Decision on New Psychoactive Substances. December 2017. Lisbon: EMCDDA.Google Scholar

Higashikawa, Y, Suzuki, S. Studies on 1-(2-phenethyl)-4-(N-propionylanilino) piperidine (fentanyl) and its related compounds. VI. Structure–analgesic activity relationship for fentanyl, methylsubstituted fentanyls and other analogues. Forensic Toxicol. 2008;26(1):1–5. doi:10.1007/s11419-007–0039–1Google Scholar

Darke, S, Duflou, J. The toxicology of heroin-related death: estimating survival times. Addiction 2016;111(9):1607–13. doi:10.1111/add.13429Google Scholar

Karinen, R, Tuv, SS, Rogde, S, et al. Lethal poisonings with AH-7921 in combination with other substances. Forensic Sci Int. 2014;244:e21–e24.Google Scholar

Armenian, P, Olson, A, Anaya, A, et al. Fentanyl and a novel synthetic opioid U-47700 masquerading as street ‘Norco’ in Central California: a case report. Ann Emerg Med. 2017;69:87–90.Google Scholar

Papsun, D, Krywanczyk, A, Vose, JC, et al. Analysis of MT-45, a novel synthetic opioid, in human whole blood by LC–MS-MS and its identification in a drug-related death. J Anal Toxicol. 2016;40(4):313–17. doi:10.1093/jat/bkw012Google Scholar

Katselou, M, Papoutsis, I, Nikolaou, P, Spiliopoulou, C, Athanaselis, S. 2015. AH-7921: the list of new psychoactive opioids is expanded. Forensic toxicology, 33(2):195–201.Google Scholar

Coppola, M, Mondola, R. AH-7921: from potential analgesic medicine to recreational drug. Int J High Risk Behav Addict. 2017;6(2):e22593. doi:10.5812/ijhrba.22593Google Scholar

Kronstrand, R, Thelander, G, Lindstedt, D, Roman, M, Kugelberg, FC. Fatal intoxications associated with the designer opioid AH-7921. Journal of Analytical Toxicology, 2014;38(8):604.Google Scholar

EMCDDA. Technical report on 3,4-dichloro-N-{[1- (dimethylamino)cyclohexyl]methyl}benzamide (AH-7921), EMCDDA, Lisbon, April 2014. www.emcdda.europa.eu/system/files/publications/774/TDAK14002ENN_480892.pdfGoogle Scholar

Elliott, S, Brandt, S, Smith, C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-Nmethylbenzamide (U-47700) and implications for forensic analysis. Drug Testing and Analysis 8(8): 875–9. http://dx.doi.org/10.1002/dta.1984Google Scholar

Helander, A, Bäckberg, M, Beck, O. MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clin Toxicol. 2014;52(8):901–4.Google Scholar

Kjellgren, A, Jacobsson, K, Soussan, C. The quest for well-being and pleasure: experiences of the novel synthetic opioids AH-7921 and MT-45, as reported by anonymous users online. J Addict Res Ther.2016;7(287):2.Google Scholar

Coppola, M, Mondola, R. MT-45: a new, dangerous legal high. J Opioid Management 2014;10:301–2.Google Scholar

Siddiqi, S, Verney, C, Dargan, P, et al. Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clin Toxicol. 2015;53(1):54–9.Google Scholar

Mohr, ALA, Friscia, M, Papsun, D, et al. Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC–MS/MS in postmortem casework. J Anal Toxicol. 2016;40:709–17. doi:10.1093/jat/bkw086.Google Scholar

Elliott, S, Brandt, S, Smith, C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-Nmethylbenzamide (U-47700) and implications for forensic analysis. Drug Testing and Analysis 2016;8(8):875–9. http://dx.doi.org/10.1002/dta.1984Google Scholar

Public Health England. Guidance for local areas on planning to deal with fentanyl or another potent opioid. 8 May 2018 www.gov.uk/government/publications/fentanyl-preparing-for-a-future-threat/guidance-for-local-areas-on-planning-to-deal-with-fentanyl-or-another-potent-opioidGoogle Scholar

Fairbairn, N, Coffin, PO, Walley, AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy 2017;46:172–9. doi:10.1016/j.drugpo.2017.06.005Google Scholar

Allan, J, Herridge, N, Griffiths, P, et al. Illicit fentanyl use in rural Australia – an exploratory study. J Alcohol Drug Depend 2015;3:196. doi:10.4172/23296488.1000196Google Scholar

Clinical Guidelines on Drug Misuse and Dependence Update. Independent Expert Working Group (2017) Drug misuse and dependence: UK guidelines on clinical management. 2017. London: Department of Health.Google Scholar

National Institute for Health and Care Excellence (NICE). Drug misuse in over 16s: opioid detoxification. Clinical guideline: 25 July 2007. www.nice.org.uk/guidance/cg52Google Scholar

Arens, AM, Xander, MD, van Wijk, MR, et al. Research letter: adverse effects from counterfeit alprazolam tablets. JAMA Internal Medicine 2016 176(10):1554–5.Google Scholar

Green, TC, Gilbert, M. Counterfeit medications and fentanyl. JAMA Intern Med. 2016;176(10):1555–7. doi:10.1001/jamainternmed.2016.4310Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation. An update from the EU Early Warning System (June 2018). 2018. Luxembourg: Publications Office of the European Union.Google Scholar

Łukasik-Głębocka, M, Sommerfeld, K, Teżyk, A, et al. Flubromazolam – a new life-threatening designer benzodiazepine. Clin Toxicol (Phila). 2016;54(1):66–8. doi:10.3109/15563650.2015.1112907.Google Scholar

Berman, RM, Cappiello, A, Anand, A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.Google Scholar

Singh, I, Morgan, C, Curran, V, et al. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. The Lancet Psychiatry 2017;4(5):419–26.Google Scholar

Corazza, O, Schifano, F, Simonato, P, et al. Phenomenon of new drugs on the internet: the case of ketamine derivative methoxetamine. Hum Psychopharmacol. 2012;27(2):145–9. doi:10.1002/hup.1242.Google Scholar

Teltzrow, R, Bosch, OG. Ecstatic anaesthesia: ketamine and GHB between medical use and selfexperimentation. Applied Cardiopulmonary Pathophysiology. 2012;16:309–21.Google Scholar

Ross, S. Ketamine and addiction. Primary Psychiatry. 2008;15(9):61–9.Google Scholar

Corazza, O, Assi, S, Schifano, F. From ‘Special K’ to ‘Special M’: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci. Ther. 2013;19(6):454–60. http://dx.doi.org/10.1111/cns.12063.Google Scholar

Siegel, RK. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Peterson, RC, Stillman, RC, eds. Phencyclidine Abuse: An Appraisal (NIDA Research Monograph 21), 1978. pp. 119–47. National Institute on Drug Abuse.Google Scholar

Morgan, CJ, Curran, HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006;188:408–24.Google Scholar

Morgan, CJA, Curran, HV. Ketamine use: a review. Addiction. 2011;107:27–38.Google Scholar

Kalsi, SS, Wood, DM, Dargan, PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J. 2011;4:7107. doi:10.3402/ehtj.v4i0.7107.Google Scholar

Wood, DM, Nicolaou, M, Dargan, PI. Epidemiology of recreational drug toxicity in a nightclub environment. Subst Use Misuse. 2009;44:1495–502.Google Scholar

Weiner, AL, Vieira, L, McKay, CA, Bayer, MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med. 2000;18:447–51.Google Scholar

Ng, SH, Tse, ML, Ng, HW, Lau, FL. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J. 2010;16(1):6–11.Google Scholar

Morgan, CJ, Muetzelfeldt, L, Curran, HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105:121–33.Google Scholar

Stewart, CE. Ketamine as a street drug. Emerg Med Serv. 2001;30(11):30, 32, 34 passim.Google Scholar

Byer, DE, Gould, AB. Development of tolerance to ketamine in an infant undergoing repeated anesthesia. Anesthesiology. 1981;54:255–6.Google Scholar

Moore, NN, Bostwick, JM. Ketamine dependence in anesthesia providers. Psychosomatics. 1999;40:356–9.Google Scholar

Critchlow, DG. A case of ketamine dependence with discontinuation symptoms. Addiction. 2006;101(8):1212–13.Google Scholar

Lim, DK. Ketamine associated psychedelic effects and dependence. Singapore Med J. 2003;44:31–4.Google Scholar

Wood, D. Ketamine and damage to the urinary tract. Addiction. 2013;108:1515–19.Google Scholar

Wood, D, Cottrell, A, Baker, SC, et al. Recreational ketamine: from pleasure to pain. BJU Int. 2011;107(12):1881–4. doi:10.1111/j.1464-410X.2010.10031.xGoogle Scholar

Yew, DT, Wood, DM, Liang, W, Tang, HC, Dargan, PI. An animal model demonstrating significant bladder inflammation and fibrosis associated with chronic methoxetamine administration. Clin Toxicol. 2013;51(4):278.Google Scholar

Muetzelfeldt, L, Kamboj, SK, Rees, H, et al. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95(3):219–29. doi:10.1016/j.drugalcdep.2008.01.024Google Scholar

Cottrell, AM, Gillat, DA. Ketamine-associated urinary pathology: the tip of the iceberg for urologists? British J Med Surg Urol. 2008;1:136–8.Google Scholar

Murray, RM, Quigley, H, Quattrone, D, Englund, A, Di Forti, M. Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry 2016;15:195–204.Google Scholar

Bonaccorso, S, Metastasio, A, Ricciardi, A, et al. Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues. Brain Sci. 2018;8(7):133. doi:10.3390/brainsci8070133CrossRefGoogle Scholar

Bäckberg, M, Tworek, L, Beck, O, Helander, JA. Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA project. Med. Toxicol. 2017;13:52–60. doi:10.1007/s13181-016–0584-2Google Scholar

Barceló, B, Pichini, S, López-Corominas, V, et al. Acute intoxication caused by synthetic cannabinoids 5F-ADB and MMB-2201: A case series. Forensic Science International 2017;273:e10–e14.Google Scholar

EMCDDA. Perspectives on drugs: Synthetic cannabinoids in Europe. www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdfGoogle Scholar

Winstock, AR, Barratt, MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013;131(1–3):106–11. doi:10.1016/j.drugalcdep.2012.12.011Google Scholar

Shafi, A, Gallagher, P, Stewart, N, Martinotti, G, Corazza, O. The risk of violence associated with novel psychoactive substance misuse in patients presenting to acute mental health services. Hum. Psychopharmacol. 2017;32:3.Google Scholar

Zarifi, C, Vyas, S. Spice-y kidney failure: A case report and systematic review of acute kidney injury attributable to the use of synthetic cannabis. Perm J 2017;21:16–160. https://doi.org/10.7812/TPP/16-160.Google Scholar

Nia, AB, Medrano, B, Perkel, C, Galynker, I, Hurd, YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis Journal of Psychopharmacology 2016;30(12):1321–30. doi:10.1177/0269881116658990Google Scholar

van Amsterdam, J, Brunt, T, van den Brink, W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of Psychopharmacology 2015;29(3):254–63.Google Scholar

Castellanos, D, Thornton, G. Synthetic cannabinoid use: recognition and management. J Psychiatr Pract. 2012;18(2):86–93. doi:10.1097/01.pra.0000413274.09305.9c.Google Scholar

Simmons, JR, Skinner, CG, Williams, J, et al. Intoxication from smoking ‘Spice’. Ann Emerg Med. 2011;57:187–8.Google Scholar

Hurst, D, Loeffler, G, McLay, R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry. 2011;168(10):1119. doi:10.1176/appi.ajp.2011.1101017.https://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2011.11010176Google Scholar

Macfarlane, V, Christie, G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug and Alcohol Review 2015;34(2):147–53.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances in prison, EMCDDA Rapid Communication. 2018. Luxembourg: Publications Office of the European Union.Google Scholar

National Offender Management Service. North West ‘Through the gate substance misuse services’ drug testing project. 2015. www.lgcgroup.com/media/1795/noms-final-phm-report-version-5.pdf.Google Scholar

Blackman, S, Bradley, R. From niche to stigma – headshops to prison: exploring the rise and fall of synthetic cannabinoid use among young adults. International Journal of Drug Policy 2017;40:70–7.Google Scholar

Ralphs, R, Williams, L, Askey, R, Norton, A. Adding spice to the porridge: the development of a synthetic cannabinoid market in an English prison. International Journal of Drug Policy 2017;40:57–69.Google Scholar

Carhart-Harris, RL, Goodwin, GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 2017;42:2105–113.Google Scholar

Garcia-Romeu, A, Kersgaard, B, Addy, PH. Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol 2016;24: 229–68.Google Scholar

Bogenschutz, MP, Forcehimes, AA, Pommy, JA, et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol 2015;29:289–99.Google Scholar

Johnson, MW, Garcia-Romeu, A, Griffiths, RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 2017;43:55–60.Google Scholar

Griffiths, RR, Johnson, MW, Carducci, MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016;30:1181–97.Google Scholar

Byock, I. Taking psychedelics seriously. Journal Of Palliative Medicine (special report). 2018;21(4).Google Scholar

Gee, P, Schep, LJ, Jensen, BP, Moore, G, Barrington, S. Case series: toxicity from 25B-NBOMe – a cluster of N-bomb cases. Clinical Toxicology 2016;54(2):141–6.Google Scholar

Timmermann, C, Roseman, L, Williams, L, et al. DMT models the near-death experience. Frontiers in Psychology 2018;9:1424.Google Scholar

Papoutsis, I, Nikolaou, P, Stefanidou, M, Spiliopoulou, C, Athanaselis, S. 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicol. 2015;33:1–11. doi:10.1007/s11419-014–0242-9Google Scholar

Deluca, P, Corazza, O, Schifano, F, et al. Bromo-dragonfly report. Psychonaut Web-Mapping Project, 2010. www.psychonautproject.eu/documents/reports/Bromodragonfly.pdfGoogle Scholar

Strassman, R. Human psychopharmacology of LSD, dimethyltryptamine and related compounds. In: Pletscher, A, Ladewig, D, eds. Fifty Years of LSD: Current Status and Perspectives of Hallucinogens, pp. 145–74. New York: Parthenon, 1994.Google Scholar

Johnstad, PG. Powerful substances in tiny amounts: An interview study of psychedelic microdosing. Nordic Studies on Alcohol and Drugs 2018;35(1):39–51.Google Scholar

Savulich, G, Piercy, T, Bruhl, AB, et al. Focusing the neuroscience and societal implications of cognitive enhancers. Clin Pharmacol Ther. 2017;101(2): 170–2.Google Scholar

d’Angelo, L-SC, Savulich, G, Sahakian, BJ. Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. British Journal of Pharmacology. 2017;174:3257–67.Google Scholar

Twemlow, SW, Bowen, WT. Psychedelic drug-induced psychological crises: attitudes of the ‘crisis therapist’. J Psychoactive Drugs. 1979;11(4):331–5.Google Scholar

Johnson, M, Richards, W, Griffiths, R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–20. doi:10.1177/0269881108093587.Google Scholar

Reich, P, Hepps, RB. Homicide during a psychosis induced by LSD. JAMA. 1972;219(7):869–71.Google Scholar

Keshavan, MS, Kaneko, Y. Secondary psychoses: an update. World Psychiatry. 2013;12(1):4–15.Google Scholar

Miyajima, M, Matsumoto, T, Ito, S. 2C-T-4 intoxication: acute psychosis caused by a designer drug. Psychiatry Clin Neurosci. 2008;62(2):243.Google Scholar

Matsumoto, T, Okada, T. Designer drugs as a cause of homicide. Addiction. 2006;101(11):1666–7.Google Scholar

Krebs, TS, Johansen, P-Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994–1002.Google Scholar

Gable, RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction. 2007;102(1):24–34.Google Scholar

Malleson, N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry. 1971;118(543):229–30.Google Scholar

Meehan, TJ, Bryant, SM, Aks, SE. Drugs of abuse: the highs and lows of altered mental states in the emergency department. Emerg Med Clin North Am. 2010;28(3):663–82. doi:10.1016/j.emc.2010.03.012.Google Scholar

Boland, DM, Andollo, W, Hime, GW, Hearn, WL. Fatality due to acute α-methyltryptamine intoxication. J Analytic Toxicol. 2005;29(5):394–7.Google Scholar

Alatrash, G, Majhail, NS, Pile, JC. Rhabdomyolysis after ingestion of ‘foxy’, a hallucinogenic tryptaminederivative. Mayo Clin Proc. 2006;81(4):550–1.Google Scholar

Gable, RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction. 2004;99(6):686–96.Google Scholar

Boland, DM, Andollo, W, Hime, GW, Hearn, WL. Fatality due to acute α-methyltryptamine intoxication. J Analytic Toxicol. 2005;29(5):394–7.Google Scholar

Gee, P, Schep, LJ, Jensen, BP, Moore, G, Barrington, S. Case series: toxicity from 25B-NBOMe – a cluster of N-bomb cases. Clinical Toxicology 2016;54(2)141–6. doi:10.3109/15563650.2015.1115056Google Scholar

Halpern, JH, Lerner, AG, Passie, T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In Halberstadt, AL, Vollenweider, FX, Nichols, DE (eds), Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol. 36. 2016. Berlin, Heidelberg: Springer.Google Scholar

Martinotti, G, Santacroce, R, Pettorruso, M, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018;8:47. doi:10.3390/brainsci8030047Google Scholar

Orsolini, L, Papanti, GD, De Berardis, D, et al. The “endless Trip” among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Frontiers in Psychiatry. 2017;8:240. doi:10.3389/fpsyt.2017.00240Google Scholar

Lerner, AG, Gelkopf, M, Skladman, I, Oyffe, I. Flashback and hallucinogen persisting perception disorder: Clinical aspects and pharmacological treatment approach. Isr. J. Psychiatry Relat. Sci. 2002;39:92–99.Google Scholar

Halpern, JH, Pope, HG. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 2003;69:109/119.Google Scholar

Hermle, L, Simon, M, Ruchsow, M, Batra, A, Geppert, M. Hallucinogen persisting perception disorder (HPPD) and flashback – are they identical? J Alcoholism Drug Depend. 2013;1:121. doi:10.4172/jaldd.1000121.Google Scholar